CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
451
Nkarta
NKTX
$154M
| $26K | ﹤0.01% |
14,155
-808
| -5% | -$1.49K |
|
452
Alector
ALEC
$300M
| $24.4K | ﹤0.01% |
19,875
-890
| -4% | -$1.1K |
|
453
Enanta Pharmaceuticals
ENTA
$192M
| $23.6K | ﹤0.01% |
4,279
-215
| -5% | -$1.19K |
|
454
Lexeo Therapeutics
LXEO
$280M
| $23K | ﹤0.01% |
6,632
-379
| -5% | -$1.32K |
|
455
C4 Therapeutics
CCCC
$191M
| $22.8K | ﹤0.01% |
14,239
-728
| -5% | -$1.17K |
|
456
Align Technology
ALGN
$9.92B
| $21.1K | ﹤0.01% |
133
| – | – |
|
457
Editas Medicine
EDIT
$232M
| $19.2K | ﹤0.01% |
16,558
-945
| -5% | -$1.1K |
|
458
Edwards Lifesciences
EW
$47.5B
| $18.6K | ﹤0.01% |
256
| – | – |
|
459
Fate Therapeutics
FATE
$113M
| $18.1K | ﹤0.01% |
22,845
-1,305
| -5% | -$1.03K |
|
460
Kyverna Therapeutics
KYTX
$159M
| $16.7K | ﹤0.01% |
8,659
-495
| -5% | -$955 |
|
461
Pliant Therapeutics
PLRX
$101M
| $16.5K | ﹤0.01% |
12,206
-697
| -5% | -$941 |
|
|
CLYM
462
Climb Bio, Inc. Common Stock
CLYM
$159M
| $16.5K | ﹤0.01% |
13,484
-770
| -5% | -$939 |
|
463
MacroGenics
MGNX
$133M
| $16K | ﹤0.01% |
12,589
-719
| -5% | -$913 |
|
464
Biomea Fusion
BMEA
$110M
| $15.5K | ﹤0.01% |
7,269
-415
| -5% | -$884 |
|
465
Repligen
RGEN
$6.92B
| $14.6K | ﹤0.01% |
115
| – | – |
|
|
ARTV
466
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.9M
| $14.6K | ﹤0.01% |
4,872
-278
| -5% | -$834 |
|
467
TScan Therapeutics
TCRX
$108M
| $13.6K | ﹤0.01% |
9,847
-563
| -5% | -$777 |
|
468
Charles River Laboratories
CRL
$8.12B
| $13.4K | ﹤0.01% |
89
| – | – |
|
469
GSK
GSK
$80.6B
| $13.2K | ﹤0.01% |
338
| – | – |
|
470
Acrivon Therapeutics
ACRV
$41.5M
| $12.7K | ﹤0.01% |
6,245
-357
| -5% | -$725 |
|
471
Quanterix
QTRX
$206M
| $12.3K | ﹤0.01% |
1,894
| – | – |
|
|
INZY
472
DELISTED
Inozyme Pharma
INZY
| $11.7K | ﹤0.01% |
12,885
-736
| -5% | -$670 |
|
473
Pyxis Oncology
PYXS
$103M
| $11.7K | ﹤0.01% |
11,928
-681
| -5% | -$667 |
|
474
Illumina
ILMN
$15.8B
| $11.6K | ﹤0.01% |
146
-33,629
| -100% | -$2.67M |
|
475
Applied Therapeutics
APLT
$68.8M
| $11.4K | ﹤0.01% |
23,339
-1,333
| -5% | -$652 |
|